Together with the fact that PDAC patients poorly respond to ICB, these results imply that an alternative mechanism functionally similar to, but molecularly distinct from, conventional immune checkpoints is responsible for oncogenic KRAS-driven reprogramming of the tumor immune microenvironment (TIME) and, consequently, for immune evasion of KRAS-mutated cancers. Here, KRAS is linked to neoplasm.